Corrigendum to: Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.
Publication
, Journal Article
Published in: Eur Heart J
November 21, 2022
Duke Scholars
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
November 21, 2022
Volume
43
Issue
44
Start / End Page
4634
Location
England
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Corrigendum to: Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. (2022). Eur Heart J, 43(44), 4634. https://doi.org/10.1093/eurheartj/ehac519
“Corrigendum to: Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.” Eur Heart J 43, no. 44 (November 21, 2022): 4634. https://doi.org/10.1093/eurheartj/ehac519.
“Corrigendum to: Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.” Eur Heart J, vol. 43, no. 44, Nov. 2022, p. 4634. Pubmed, doi:10.1093/eurheartj/ehac519.
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
November 21, 2022
Volume
43
Issue
44
Start / End Page
4634
Location
England
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology